investor.sppirx.comInvestor Relations - Spectrum Pharmaceuticals, Inc.

Skip to main navigation Our Company Our Company Company Philosophy Corporate Compliance Partnerships Management Board of Directors Careers Development Pipeline Pipeline ROLONTIS® (eflapegrastim) Poziotinib Glossary Investor Relations Investor Relations Press Releases Events and Presentations Corporate Governance Corporate Governance Management Board of Directors Committee Composition Insider Transactions Annual Report and Proxy Information Financial Information Financial Information SEC Filings 10K Annual Reports Quarterly Results Financial Statements Stock Information Stock Information Historic Stock Lookup Investment Calculator Stock-Split History Analyst Coverage Ownership Profile Investor FAQs Medical Professionals Medical Professionals Clinical Trials Grants Investigator Initiated Trials Expanded Access Program Careers Contact Us Investor Relations Home Investor Relations DAY HI: DAY LOW: VOLUME: Copyright West LLC. Minimum 15 minutes delayed. Shareholder Tools Printed Materials Email Alerts Download Library RSS Feeds Print Investor Relations Corporate Profile Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncology and Hematology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy. Spectrum Pharmaceuticals' stock is traded through the Nasdaq Global Market System. Ticker Symbol: SPPI INTRA 3 MO. 6 MO. 1 YR. Copyright West LLC. Minimum 15 minutes delayed. Copyright West LLC. Minimum 15 minutes delayed. Copyright West LLC. Minimum 15 minutes delayed. Copyright West LLC. Minimum 15 minutes delayed. Recent Releases View All Press Releases Dec 26, 2019 Spectrum Pharmaceuticals Provides Pipeline Update on Late Stage Programs Read More Nov 14, 2019 Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 London Healthcare Conference on November 21st Read More Nov 07, 2019 Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update Read More Our Company Company Philosophy Corporate Compliance Partnerships Management Board of Directors Careers Development Pipeline Pipeline ROLONTIS® (eflapegrastim) Poziotinib Glossary Investor Relations Press Releases Events and Presentations Corporate Governance Annual Report and Proxy Information Financial Information Stock Information Investor FAQs Medical Professionals Clinical Trials Medical Affairs Grants Investigator Initiated Trials Careers Contact Us This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law. All contents copyright Spectrum Pharmaceuticals, Inc. © 2020. All Rights Reserved. PP-ALL-00-0021 Site Map Privacy Policy Terms of Use Linking Policy Contact Us Remote Support Webmail...